{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:16:18Z","timestamp":1791260178175,"version":"4.1.0"},"reference-count":50,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T00:00:00Z","timestamp":1606608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["JoF"],"abstract":"<jats:p>Increasing incidence of invasive fungal infections combined with a growing population of immunocompromised hosts has created a rising need for antifungal agents. Isavuconazole, a second-generation broad-spectrum triazole with activity against yeasts, dimorphic fungi, and molds, has a favorable safety profile and predictable pharmacokinetics. Patients typically tolerate isavuconazole well with fewer drug\u2013drug interactions. Clinical trials have found it to be noninferior to voriconazole for invasive aspergillosis, an alternative therapy for salvage treatment of mucormycosis, and suitable for stepdown therapy with invasive candidiasis. Cross-resistance with other triazoles is common. More studies are needed to determine the role of isavuconazole in anti-mold prophylaxis in high-risk patients.<\/jats:p>","DOI":"10.3390\/jof6040324","type":"journal-article","created":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T21:00:57Z","timestamp":1606683657000},"page":"324","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance"],"prefix":"10.3390","volume":"6","author":[{"given":"Misti","family":"Ellsworth","sequence":"first","affiliation":[{"name":"Division of Pediatric Infectious Diseases, UT Health McGovern Medical School, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ostrosky-Zeichner","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, UT Health McGovern Medical School, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: Human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bongomin, F., Gago, S., Oladele, R.O., and Denning, D.W. (2017). Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J. Fungi, 3.","DOI":"10.3390\/jof3040057"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14656566.4.2.147","article-title":"Antifungal pharmacotherapy for invasive mould infections","volume":"4","author":"Gallagher","year":"2003","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/17425255.2012.683859","article-title":"Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections","volume":"8","author":"Livermore","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/DDDT.S145545","article-title":"Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: Design, development, and place in therapy","volume":"12","author":"Jenks","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH","volume":"54","author":"Desai","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e00101-17","DOI":"10.1128\/AAC.00101-17","article-title":"Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole","volume":"61","author":"Kovanda","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","article-title":"Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Roos","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","article-title":"Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Roos","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","unstructured":"Everson, N., Smith, J., and Garner, D. (2015, January 25\u201328). Successful treatment of contaminated epidural steroid associated fungal menigitis with isauvconazole. Proceedings of the European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Copenhagen, Denmark. Abstract P0231."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e01292-17","DOI":"10.1128\/AAC.01292-17","article-title":"Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats","volume":"61","author":"Kato","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00514-16","article-title":"Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)","volume":"60","author":"Kovanda","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"Kaindl","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00228-017-2213-7","article-title":"Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics","volume":"73","author":"Townsend","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zurl, C., Waller, M., Schwameis, F., Muhr, T., Bauer, N., Zollner-Schwetz, I., Valentin, T., Meinitzer, A., Ullrich, E., and Wunsch, S. (2020). Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations. J. Fungi, 6.","DOI":"10.3390\/jof6020090"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/phar.2348","article-title":"Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation","volume":"40","author":"Zhao","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e00585-18","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/cid\/ciw444","article-title":"Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cmi.2017.03.023","article-title":"Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates","volume":"23","author":"Astvad","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1128\/AAC.01217-06","article-title":"In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates","volume":"51","author":"Seifert","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1128\/AAC.04055-14","article-title":"Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method","volume":"59","author":"Chowdhary","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e00578","DOI":"10.1002\/mbo3.578","article-title":"Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen","volume":"7","year":"2018","journal-title":"Microbiologyopen"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1128\/JCM.01190-13","article-title":"Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility","volume":"51","author":"Datta","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cpt.620","article-title":"QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization","volume":"101","author":"Keirns","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/myc.12731","article-title":"Isavuconazole shortens the QTc interval","volume":"61","author":"Mellinghoff","year":"2018","journal-title":"Mycoses"},{"key":"ref_30","unstructured":"Astellas Pharma US & Inc. (2020, September 30). CRESEMBA (isavuconazonium_sulfate) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207500Orig1s000lbl.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e13007","DOI":"10.1111\/tid.13007","article-title":"Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study","volume":"21","author":"Kieu","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/myc.12885","article-title":"Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events","volume":"62","author":"Bongomin","year":"2019","journal-title":"Mycoses"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12325-016-0443-1","article-title":"Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis","volume":"34","author":"Harrington","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13696998.2019.1638789","article-title":"The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom","volume":"23","author":"Floros","year":"2020","journal-title":"J. Med. Econ."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Floros, L., Kuessner, D., Posthumus, J., Bagshaw, E., and Sj\u00f6lin, J. (2019). Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3683-2"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis","volume":"54","author":"Petrikkos","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/myc.12769","article-title":"Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial","volume":"61","author":"Perfect","year":"2018","journal-title":"Mycoses"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/INF.0000000000002671","article-title":"Isavuconazole As Successful Salvage Therapy for Mucormycosis in Pediatric Patients","volume":"39","author":"Bilavsky","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e00591","DOI":"10.1016\/j.idcr.2019.e00591","article-title":"Rhinoorbital mucormycosis in the immunocompetent: Experience with Isavuconazole","volume":"18","author":"Ilharco","year":"2019","journal-title":"IDCases"},{"key":"ref_43","first-page":"e2547","article-title":"Isavuconazole: A Promising Salvage Therapy for Invasive Mucormycosis","volume":"10","author":"Shafiq","year":"2018","journal-title":"Cureus"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ricotta, E.E., Lai, Y.L., Babiker, A., Strich, J.R., Kadri, S.S., Lionakis, M.S., Prevots, D.R., and Adjemian, J. (2020). Invasive candidiasis species distribution and trends, United States, 2009\u20132017. J. Infect. Dis.","DOI":"10.1093\/infdis\/jiaa502"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: A persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2147\/TCRM.S90335","article-title":"Role of isavuconazole in the treatment of invasive fungal infections","volume":"12","author":"Wilson","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/AAC.02157-15","article-title":"Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms","volume":"60","author":"Sanglard","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2011.11.001","article-title":"Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment","volume":"125","author":"Pfaller","year":"2012","journal-title":"Am. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e00073-19","DOI":"10.1128\/AAC.00073-19","article-title":"EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates","volume":"63","author":"Astvad","year":"2019","journal-title":"Antimicrob. Agents Chemother."}],"updated-by":[{"DOI":"10.3390\/jof11030226","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T00:00:00Z","timestamp":1606608000000}}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/6\/4\/324\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T14:24:50Z","timestamp":1754231090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/6\/4\/324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,29]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["jof6040324"],"URL":"https:\/\/doi.org\/10.3390\/jof6040324","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,29]]}}}